Julia Rudno-Rudzinska

Julia Rudno-Rudzinska

Auto-generated profile, based on publicly available information

Julia Rudno-Rudzinska

2nd Department of General and Oncological Surgery, Wroclaw Medical University, Borowska 213, 50-556, Wrocław, Poland,

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2012 in Gastric Cancer
Verified
Journal Article
Open access
PDF file
JRJulia Rudno-Rudzinska
Julia Rudno-Rudzinska
WKWojciech Kielan
Wojciech Kielan
ZGZygmunt Grzebieniak
Zygmunt Grzebieniak
Piotr DziegielPiotr Dziegiel
Piotr Dziegiel
PDPiotr Donizy
Piotr Donizy
AHAgnieszka Halon
Agnieszka Halon
Background One of the most important prognostic indicators in gastric cancer is the presence of metastases in lymph nodes. Even now, little is known about lymphangiogenesis in neoplastic tissue, and little is also known about the transmission of a neoplastic cell from the tumor mass into a lymphatic vessel. Methods This study examined the relationships between the density of lymphatic vessels (LVD) stained immunohistochemically with lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) and D2-40 (podoplanin) antibodies, the expression of vascular endothelial growth factor (VEGF)-C/D, selected clinical and pathomorphological factors, and the 5-year overall survival of gastric cancer patients. Results Statistical analysis showed no impact of increased intratumoral or peritumoral LVD on gastric cancer patient survival, irrespective of the protein used to stain lymphatic vessels. Analysis showed that the probability of overall survival was decreased in the cases with enhanced VEGF-D immunoreactivity (P = 0.0045). Conclusion The study showed that the studied markers cannot be used to determine the required extent of the surgical procedure, as they have no statistically significant correlation with the degree of progression of the cancer, the stage of the disease assessed according to the TNM 5th classification of malignant tumors, clinicopathological features, and patient survival. VEGF-D is the only marker that can be regarded as an unfavorable prognostic indicator for patients with advanced gastric cancer.